Details About Generic Salt ::  Flutamid

Main Medicine Class::    

FLEW-tuh-mide

Eulexin

Capsules for oral use

125 mg

Class: Antiandrogen

Antineoplastic hormone

 Indications Metastatic prostate cancer, combination therapy with a luteinizing hormone-releasing hormone analog (eg, goserelin, leuprolide).

Treatment of hirsutism in women (250 mg/day).

 Contraindications Patients with severe hepatic impairment.

 Route/Dosage

Prostate Cancer

ADULTS: PO 250 mg (2 capsules) q 8 hr.

Stage B₂-C Prostatic Carcinoma

ADULTS: PO Treatment should start 8 wk prior to initiating radiation therapy and continue during radiation therapy.

Stage D₂ Metastatic Carcinoma

ADULTS: PO Initiate flutamide capsules with the LHRH agonist and continue until progression.

Interactions Prothrombin time may increase when flutamide therapy is initiated in patients stabilized on chronic warfarin therapy.

Lab Test Interferences Elevated AST, ALT, bilirubin, SGGT, BUN, and serum creatinine.

 Adverse Reactions

CNS: Decreased libido. ENDOCRINE: Hot flashes, gynecomastia. GI: Low potential for nausea and vomiting; diarrhea; hepatocellular necrosis; cholestatic jaundice; elevated LFTs. GU: Impotence; reduced sperm count.

 Precautions

Pregnancy: Category D. Aniline exposure: A metabolite of flutamide, 4-nitro-3-fluoro-methylaniline, may cause methemoglobinemia, hemolytic anemia, and cholestatic jaundice in patients treated with flutamide. Hepatic injury: Hospitalization and rarely death from liver failure. Evidence of hepatic injury included elevated serum transaminase levels, jaundice, hepatic encephalopathy, and death related to acute hepatic failure. The hepatic injury was reversible after discontinuation of therapy in some patients. Approximately 50% of the reported cases occurred within the initial 3 mo of treatment. Women: Flutamide is for use only in men.

PATIENT CARE CONSIDERATIONS

 Administration/Storage

• Store capsules in refrigerator or at room temperature; protect from moisture.
• For PO administration.
• For patients unable to swallow capsules, open the capsule and mix the contents with applesauce, pudding, or other semi-solid foods. Administer immediately.

 Assessment/Interventions

• Monitor serum transaminase levels at baseline and monthly during the first 4 mo of treatment. Monitor periodically during continued treatment, especially if the patient experiences signs and symptoms of liver dysfunction. Immediately discontinue flutamide if ALT increases > 2 times above the upper limit of normal.
• Monitor methemoglobin levels in patients susceptible to aniline toxicity (eg, people with glucose-6-phosphate dehydrogenase deficiency or hemoglobin M disease as well as patients who smoke).
• Regular assessment of serum prostate specific antigen (PSA) may be helpful in monitoring the patient’s response.

OVERDOSAGE: SIGNS & SYMPTOMS   Hypoactivity; piloerection; slow respiration; ataxia; lacrimation; anorexia; tranquilization; emesis; methemoglobinemia

 Patient/Family Education

• The urine was noted to change to an amber or yellow-green appearance.
• Photosensitization may occur.
• Flutamide and LHRH-agonists should be administered concomitantly; and do not interrupt dosing or stop taking these medications without consulting the health care provider.

Medicscientist Drug Facts

Drugs Class ::

Indications for Drugs ::

 Indications Metastatic prostate cancer, combination therapy with a luteinizing hormone-releasing hormone analog (eg, goserelin, leuprolide).

Treatment of hirsutism in women (250 mg/day).

Drug Dose ::

 Route/Dosage

Prostate Cancer

ADULTS: PO 250 mg (2 capsules) q 8 hr.

Stage B₂-C Prostatic Carcinoma

ADULTS: PO Treatment should start 8 wk prior to initiating radiation therapy and continue during radiation therapy.

Stage D₂ Metastatic Carcinoma

ADULTS: PO Initiate flutamide capsules with the LHRH agonist and continue until progression.

Contraindication ::

 Contraindications Patients with severe hepatic impairment.

Drug Precautions ::

 Precautions

Pregnancy: Category D. Aniline exposure: A metabolite of flutamide, 4-nitro-3-fluoro-methylaniline, may cause methemoglobinemia, hemolytic anemia, and cholestatic jaundice in patients treated with flutamide. Hepatic injury: Hospitalization and rarely death from liver failure. Evidence of hepatic injury included elevated serum transaminase levels, jaundice, hepatic encephalopathy, and death related to acute hepatic failure. The hepatic injury was reversible after discontinuation of therapy in some patients. Approximately 50% of the reported cases occurred within the initial 3 mo of treatment. Women: Flutamide is for use only in men.

Drug Side Effects ::

 Adverse Reactions

CNS: Decreased libido. ENDOCRINE: Hot flashes, gynecomastia. GI: Low potential for nausea and vomiting; diarrhea; hepatocellular necrosis; cholestatic jaundice; elevated LFTs. GU: Impotence; reduced sperm count.

Drug Mode of Action ::  

Drug Interactions ::

Interactions Prothrombin time may increase when flutamide therapy is initiated in patients stabilized on chronic warfarin therapy.

Drug Assesment ::

 Assessment/Interventions

• Monitor serum transaminase levels at baseline and monthly during the first 4 mo of treatment. Monitor periodically during continued treatment, especially if the patient experiences signs and symptoms of liver dysfunction. Immediately discontinue flutamide if ALT increases > 2 times above the upper limit of normal.
• Monitor methemoglobin levels in patients susceptible to aniline toxicity (eg, people with glucose-6-phosphate dehydrogenase deficiency or hemoglobin M disease as well as patients who smoke).
• Regular assessment of serum prostate specific antigen (PSA) may be helpful in monitoring the patient’s response.

Drug Storage/Management ::

 Administration/Storage

• Store capsules in refrigerator or at room temperature; protect from moisture.
• For PO administration.
• For patients unable to swallow capsules, open the capsule and mix the contents with applesauce, pudding, or other semi-solid foods. Administer immediately.

Drug Notes ::

 Patient/Family Education

• The urine was noted to change to an amber or yellow-green appearance.
• Photosensitization may occur.
• Flutamide and LHRH-agonists should be administered concomitantly; and do not interrupt dosing or stop taking these medications without consulting the health care provider.

Medicscientist Drug Facts

Disclaimer ::

The Information available on this site is for only Informational Purpose , before any use of this information please consult your Doctor .Price of the drugs indicated above may not match to real price due to many possible reasons may , including local taxes etc.. These are only approximate indicative prices of the drug.